Navigation Links
Microbiologists receive top Canadian recognition
Date:5/8/2008

One is a veteran researcher, the other new, but two microbiologists from The University of Western Ontario have both been singled out to receive national recognition for their work on infectious diseases and immunity from the Canadian Society of Microbiologists (CSM).

Dr. Miguel Valvano, a professor and Chair of the Department of Microbiology and Immunology at the Schulich School of Medicine & Dentistry received the prestigious CSM/Roche Diagnostics Award for outstanding accomplishments and Dr. John McCormick, an assistant professor in the Department of Microbiology received the Fisher Scientific Award for new researchers in microbiological sciences.

Valvano, who also holds a Canada Research Chair in Infectious Diseases and Microbial Pathogenesis, received his M.D. from the University of Buenos Aires, and trained as paediatrician and infectious diseases specialist in the Buenos Aires Childrens Hospital, and later as a molecular biologist in the Oregon Health Sciences University, before joining Western in 1988. His team discovered the way to kill B. cenocepacia, a superbug which can be highly contagious and deadly for those with cystic fibrosis. This discovery paves the way for the development of new antibiotics to treat it, as well as a vaccine to prevent it. We are investigating how bacteria make their outer surface and how can we find novel ways to interfere with this process, says Valvano.

A critical aspect of our research is also to train graduate students and postdoctoral fellows to become outstanding biomedical scientists within an environment of scientific inquiry, and particularly placing an emphasis on personal and scientific integrity and on team player skills.

McCormick received his Ph.D. from the University of Alberta and continued post-doctoral training in the U.S. before coming to Western in 2002. McCormick is also a scientist with the Lawson Health Research Institute and he holds a New Investigator awar
'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Page: 1 2

Related medicine news :

1. U.S. Navy Receives Funding for Further Development of Hemopure(R)
2. UCSF receives funding for building from California stem cell agency
3. USC receives nearly $27 million in funding for new stem cell research facility
4. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
5. Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence
6. Boston Medical Center/Boston University School of Medicine researcher receives award
7. Canadian Company Receives Final Tender Approval From Rwanda For Vital AIDS Drug
8. Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants
9. Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification
10. Vascular Insights Receives FDA Clearance for Infusion Catheter
11. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
(Date:9/21/2014)... 2014 An experienced review website in ... hosting ranking list and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ... suppliers. , There has been a boom in ... resulted in an increase in the number of web ... at very affordable prices. VPS (Virtual Private Server) is ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. District ... 20 possible C8 lawsuits selected for bellwether trials ... & Schulte LLC. Court records show these six C8 ... filed that represent individuals who purportedly developed kidney cancer, ... being exposed to water contaminated by the C8 chemical ...
(Date:9/20/2014)... Vegas, NV (PRWEB) September 21, 2014 ... by Dr. Kenneth Pullman that is helping thousands of ... their diabetes symptoms without shots, pills, or prescriptions has ... review. , “There are currently tens of millions ... both Type 1 and Type 2 diabetes, and unfortunately, ...
(Date:9/20/2014)... Islands of Loreto, Baja, Mexico (PRWEB) September 20, 2014 ... of Loreto today announced the resort did not experience ... fully operational, with all amenities and activities available. , ... September 14, 2014, bringing intense wind, rain and powerful ... Baja Peninsula, Villa del Palmar Islands of Loreto experienced ...
Breaking Medicine News(10 mins):Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3
... following Congress, failure,to override SCHIP veto, WASHINGTON, Oct. ... Fattah:, "It,s a sad day when America,s children ... for and look after their most basic needs. It,s,a ... defend its most,vulnerable citizens., "The failure of the ...
... Must Happen Before Congressional Thanksgiving Break on State,Children,s ... "Congress cannot go home,to its Thanksgiving break ... of mind for America,s laboring families by passing ... Delgado, President and CEO of the,National Alliance for ...
... the Northern California Cancer Center, the University of Southern ... found that increased exposure to sunlight which increases ... decrease the risk of advanced breast cancer. , In ... Journal of Epidemiology, the researchers found that women with ...
... 2007 Research will be reported at TCT 2007, ... (CRF), that demonstrates that early intervention saves lives in ... pain. , Responding to media reports of recent studies ... to men, Dr. Alexandra J. Lansky, MD, Director of ...
... half of sufferers are kept awake by a variety of ... Along with typical symptoms such as acid reflux, the less ... coughing, choking, wheezing, choking, snoring, sore throat, and chest pain ... new U.S. survey. , The poll of 701 GERD patients ...
... Oct. 18 Following is a statement from ... the House,s failure to,override President Bush,s veto of ... of the Congressional Democrats and,some courageous Republicans to ... health care to children whose parents cannot,afford it. ...
Cached Medicine News:Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 2Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 3Health News:Are women at greater risk from angioplasty? 2
(Date:9/19/2014)... , Sept. 19, 2014 Today, iHealth Lab ... from Xiaomi Ventures, Ltd. for its first institutional round ... continue expanding iHealth,s global reach, accelerate growth and innovation, ... part of the investment, Xiaomi Ventures will join iHealth,s ... of cloud infrastructure and ecommerce. "We are ...
(Date:9/19/2014)... Kiromic, LLC, a Lubbock bio-pharmaceutical company, ... former chancellor of Texas Tech University, to its board as ... after raising $1.2 billion for the university. "Kiromic ... most successful chancellor in the history of Texas Tech University, ... but also as our new vice chairman of the board. ...
(Date:9/19/2014)... N.C. , Sept. 19, 2014  For ... cloud-based drug design and development, partnering is an ... mission is to design new drugs and identify ... 2 partners to further their development. The company ... investments. To support this business model, Cloud Pharmaceuticals ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Data in Pediatric Patients,Presented at the American ... N.J., Nov. 11 Daiichi Sankyo,Inc. (DSI), ... study supporting,the use of colesevelam HCl in ... presented for the first time at the,American ...
... 3.5 Fold Higher ... Compared to Standard Chemotherapy, SEATTLE, Nov. 11 ... it achieved the primary,efficacy endpoint of its phase III EXTEND ... non-Hodgkin,s,lymphoma (NHL) based on a preliminary intent to treat efficacy ...
Cached Medicine Technology:Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 6Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 7Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4
Wire lid retractor, may be clamped to surgical drape with suture or elastic band. Small pair....
Flexible rake retractor, 3 blunt prongs....
Bayonet dressing forceps serrated jaws...
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
Medicine Products: